

Format for ANSWERING REVIEWERS

April 17, 2013

Dear Editor,



Please find enclosed the edited manuscript in Word format (file name: 2713-review.doc).

Title: Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 Polymorphisms

Author: Jian Ming Xu, Yan Wang, Fei Jiao Ge, Li Lin, Ze Yuan Liu, Manish R. Sharma

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 2713

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) Core Tip has been added.

(2) UGT1A1*6 and UGT1A1*28 decrease UGT1A1 activity via different mechanisms, the former variant lessens protein function directly, whereas the latter reduces transcriptional activity of the promoter. Genetic effects on UGT activity compensate for each other, heterozygous for both UGT1A1*6 and UGT1A1*28 (UGT1A1*6/UGT1A1*28 diplotype) resulting in remarkably lower UGT activity. However, homozygous UGT1A1*6 and homozygous UGT1A1*28 are thought to be mutually exclusive, So the coexistence of homozygous UGT1A1*6 and UGT1A1*28 does not exist.

3 Language guarantee

I have more than 15 papers published in different English medical journals, including European journal of cancer, BMC Cancer, Cancer Research and Clinical Oncology. Recently a paper named "UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil" had been published in World Journal of Gastroenterology. So I believe that the language of my manuscript has reached Grade A.

Thank you again for publishing our manuscript in the World Journal of Gastroenterology.

Sincerely yours,

Jian Ming Xu, MD
Affiliated Hospital
Cancer Center, Academy
of Military Medical Sciences
Fax: +86-10-51128358
E-mail: jmxu2003@yahoo.com